SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.

Other languages Shenzhen Chipscreen Biosciences Co., Ltd.

Equities

688321

CNE100003LW0

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
21.4 ^CNY	-2.73%		-8.94%	-2.51%

Apr. 30	National Medical Products Administration Approves Chipscreen Biosciences Co., Ltd.'s Chidamide Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma	CI
Apr. 28	Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

National Medical Products Administration Approves Chipscreen Biosciences Co., Ltd.'s Chidamide Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma	Apr. 30
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 28
Shenzhen Chipscreen Biosciences Co., Ltd. commences an Equity Buyback Plan for CNY 15 million worth of its shares, under the authorization approved on February 22, 2024.	Mar. 26
Shenzhen Chipscreen Biosciences Co., Ltd. Announces Positive Results from Phase II Clinical Trial (CGZ203 Study) of Chiglitazar Monotherapy for Non-Alalcoholic Steatohepatitis	Mar. 18
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-11
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27
Biocytogens Tochtergesellschaft Eucure Biopharma und die Tochtergesellschaft der Holding Chipscreen Biosciences, Chipscreen NewWay Biosciences, schließen einen Lizenzvertrag für die Region China über den bispezifischen Antikörper YH008	23-02-27
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29
Akeso, Chipscreen Bio to Jointly Carry Out Clinical Trials of Combination Therapy for Lung Cancer	22-03-02
Akeso, Inc. Announces Collaboration with Chipscreen Biosciences to Initiated A Clinical Trial of Pd-1/Ctla-4 Bi-Specific Antibody in Combination with Chiauranib for Pd-(L)1 Pretreated Es-Sclc	22-03-02
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25
Ascletis Pharma Arm Supplies Antibody for Trial of Combination HIV Treatment	22-02-15
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-29
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-29
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shenzhen Chipscreen Biosciences Co., Ltd.

Equities

688321

CNE100003LW0

Other languages

Filters